These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 16565470)

  • 41. 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.
    Zaragoza F; Stephensen H; Peschke B; Rimvall K
    J Med Chem; 2005 Jan; 48(1):306-11. PubMed ID: 15634025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.
    Covel JA; Santora VJ; Smith JM; Hayashi R; Gallardo C; Weinhouse MI; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Pulley MD; Smith BM; Ren A; Suarez M; Frazer J; Edwards J; Hauser EK; Lorea J; Semple G; Grottick AJ
    J Med Chem; 2009 Sep; 52(18):5603-11. PubMed ID: 19722526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia.
    Johnson CN; Ahmed M; Miller ND
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):642-54. PubMed ID: 18729016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
    Cowart M; Faghih R; Curtis MP; Gfesser GA; Bennani YL; Black LA; Pan L; Marsh KC; Sullivan JP; Esbenshade TA; Fox GB; Hancock AA
    J Med Chem; 2005 Jan; 48(1):38-55. PubMed ID: 15634000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The histamine H3 receptor and eating behavior.
    Passani MB; Blandina P; Torrealba F
    J Pharmacol Exp Ther; 2011 Jan; 336(1):24-9. PubMed ID: 20864503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
    Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overview: H3 histamine receptor isoforms: new therapeutic targets in the CNS?
    Chazot PL; Hann V
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1428-31. PubMed ID: 11890359
    [No Abstract]   [Full Text] [Related]  

  • 48. Phenyl-oxazoles, a new family of inverse agonists at the H(3) histamine receptor.
    Denonne F; Atienzar F; Célanire S; Christophe B; Delannois F; Delaunoy C; Delporte ML; Durieu V; Gillard M; Lallemand B; Lamberty Y; Lorent G; Vanbellinghen A; Van Houtvin N; Verbois V; Provins L
    ChemMedChem; 2010 Feb; 5(2):206-12. PubMed ID: 20043314
    [No Abstract]   [Full Text] [Related]  

  • 49. Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists.
    Hancock AA; Brune ME
    Expert Opin Investig Drugs; 2005 Mar; 14(3):223-41. PubMed ID: 15833055
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists.
    Cowart M; Altenbach R; Black L; Faghih R; Zhao C; Hancock AA
    Mini Rev Med Chem; 2004 Nov; 4(9):979-92. PubMed ID: 15544558
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic potential of histamine H3 receptor agonists and antagonists.
    Leurs R; Blandina P; Tedford C; Timmerman H
    Trends Pharmacol Sci; 1998 May; 19(5):177-83. PubMed ID: 9652190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advances in histamine H3 receptor antagonists/inverse agonists.
    Łazewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2010 Sep; 20(9):1147-69. PubMed ID: 20716022
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Constitutive activity of the histamine H3 receptor.
    Arrang JM; Morisset S; Gbahou F
    Trends Pharmacol Sci; 2007 Jul; 28(7):350-7. PubMed ID: 17573125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-imidazole histamine H3 ligands. Part III. New 4-n-propylpiperazines as non-imidazole histamine H3-antagonists.
    Walczyński K; Zuiderveld OP; Timmerman H
    Eur J Med Chem; 2005 Jan; 40(1):15-23. PubMed ID: 15642406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
    Zhao C; Sun M; Bennani YL; Gopalakrishnan SM; Witte DG; Miller TR; Krueger KM; Browman KE; Thiffault C; Wetter J; Marsh KC; Hancock AA; Esbenshade TA; Cowart MD
    J Med Chem; 2008 Sep; 51(17):5423-30. PubMed ID: 18683917
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-activity relationships of A-331440: a new histamine-3 antagonist with anti-obesity properties.
    Faghih R; Esbenshade TA; Krueger KM; Yao BB; Witte DG; Miller TM; Kang CH; Fox GB; Cowart M; Bennani YL; Hancock AA
    Inflamm Res; 2004 Mar; 53 Suppl 1():S79-80. PubMed ID: 15054629
    [No Abstract]   [Full Text] [Related]  

  • 57. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
    Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
    Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
    [No Abstract]   [Full Text] [Related]  

  • 58. Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents.
    Petroianu G; Arafat K; Sasse BC; Stark H
    Pharmazie; 2006 Mar; 61(3):179-82. PubMed ID: 16599255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histamine H3 receptor antagonists go to clinics.
    Sander K; Kottke T; Stark H
    Biol Pharm Bull; 2008 Dec; 31(12):2163-81. PubMed ID: 19043195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The histamine H3 receptor: from discovery to clinical trials with pitolisant.
    Schwartz JC
    Br J Pharmacol; 2011 Jun; 163(4):713-21. PubMed ID: 21615387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.